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DIFFERENCE FOR THE ESPRINT-15 QUESTIONNAIRE FOR
PATIENTS WITH ALLERGIC RINHITIS
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13D Health Research, Barcelona, Spain; 2Esprint Study Investigators
Group, Barcelona, Spain
OBJECTIVE: To determine the minimal clinically important dif-
ference (MCID) for improving interpretation of the recently val-
idated Esprint-15 questionnaire, to measure health-related
quality of life for patients with allergic rhinitis. METHODS: An
observational multicenter study was carried out with allergic
rhinitis patients to validate the Esprint questionnaire (15 items
of symptoms, daily life activity, sleep and psychological impact).
It uses 7-point response options. Global score range from zero
(worse) to 5.8 (better). MCID was determined by applying the
method previously used by Juniper et al. (1996) in the case of
the Rhinoconjuntivitis Quality of Life questionnaire. Patients
completed twice the Esprint-15 and assessed their change on
health status in a 13-point scale from -6 (a very great deal worse)
to 0 (no change) to +6 (a very great deal better). Patients were
classiﬁed as “no change” (-1, 0 or +1), “MCID” (+3 or +2),
“moderate change” (+4 or +5) and “large change” (+6).
RESULTS: Valid responses for the 2 visits were obtained from
245 patients (mean age 32, 62.2% women, average of moderate
symptoms at inclusion, mean 7 years from diagnosis, 58% were
following AR treatment) of which: 30 (12.2%) reported “large
change”, 86 (35.1%) reported “moderate change”, 55 (22.4%)
reported “MCID”, 48 (19.6%) reported “no change” and 25
(10.2%) reported deterioration in health status. Mean (SD)
increases in the Esprint-15 global score were: 0.2 (0.9) for
patients with “no change”, 1.1 (0.9) for patients at the “MID”,
2 (1.1) for patients reporting “moderate change”, and 2.9 (1.2)
for patients reporting “large change”. Because of the small
sample size, results for patients reporting negative changes are
not presented, although they suggest an attenuate but similar ten-
dency. CONCLUSION: There is evidence that mean positive
changes in global score from Esprint-15 questionnaire of about
1 or more may be considered of clinical importance.
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OBJECTIVE: The main objective of the research is to understand
the perceived key attributes and strengths of the FDT formula-
tion of Ebastine. METHODS: The new formulation Ebastine
FDT was tested using placebo both in patients (60) and physi-
cians (82) throughout qualitative face-to-face interviews in
Belgium, France, Finland, Germany and Italy. Patients suffering
from chronic or acute/seasonal allergies regularly taking pre-
scription antihistamines and physicians who are high prescribers
of antihistamines were included. RESULTS: The key attributes
for preference of the new FDT formulation are convenience and
ease of use (can be taken everywhere, not water is needed) and
the perception of faster onset of action. After tasting there’s a
positive evaluation for the majority (57 patients out of 60 and
75 physicians out of 82) on most FDT formulation attributes
(correct texture, appearance, colour and size and very rapid dis-
solving). Taste evaluation was controversial (mint ﬂavour) and
patients difﬁculties handling the blister disappeared when
instructed. The FDT formulation is perceived as suitable for any
type of patients, particularly those with acute episodes, active
lifestyle, difﬁculties to swallow and gastrointestinal problems
according to patients; and those with an active lifestyle accord-
ing to physicians. Most patients consider that the new formula-
tion can improve compliance (45 out of 60). The likelihood of
taking/prescribing Ebastine FDT is quite high, rating 7.9 (4.2)
and 7.6 (5.7) respectively for patients and physicians on a 1–10
scale (1–7 scale in Finland). Most patients (47 out of 60) and
physicians (54 out of 82) preferred the new FDT formulation.
CONCLUSIONS: The new FDT formulation is preferred by
both physicians and patients, because it’s easier to comply, more
convenient and it’s associated with a perception of faster onset
of action.
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SPECIFIC IMMUNO-THERAPY
Arnould B1, Benmedjahed K2, Fadel R3, Bos C3, Fontaine JF4,
Haddad T5, Mathelier Fusade P5, Ruﬁn P5, Saint Martin F6, Zekri J7,
Viala M2
1Mapi Values, Lyon, Rhone, France; 2Mapi Values, Lyon, France;
3Stallergènes, Antony, France; 4Private practice, Reims, France; 5Private
practice, Paris, France; 6Private practice,Villebon sur Yvette, France;
7Private practice,Toulouse, France
OBJECTIVE: Clinicians in charge of allergic rhinitis patients
miss speciﬁc questionnaires assessing patients’ expectations, sat-
isfaction, adherence, persistence, attitudes toward Speciﬁc
Immuno-therapy (SIT). Our aim was to provide them with a spe-
ciﬁc instrument allowing bettering adapting care to the patient’s
characteristics, perceptions and behaviour. METHODS: A con-
ceptual model was identiﬁed from a literature review, 5 clinician
and 21 patient interviews. A test version of the questionnaire was
developed and independently validated by an Advisory Com-
mittee (AC). Five patients suffering from allergic rhinitis and
treated by SIT completed the questionnaire and were asked to
comment the questionnaire in-depth. It was redrafted and
included in a pilot study (10 clinicians, 30 patients) in real con-
ditions of use. A revised questionnaire was administrated by 211
clinicians to 571 patients (380 having a SIT and 191 about to)
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